Cargando…
Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
BACKGROUND: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity, in pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085927/ https://www.ncbi.nlm.nih.gov/pubmed/36496489 http://dx.doi.org/10.1245/s10434-022-12661-3 |
_version_ | 1785022033446305792 |
---|---|
author | Liesenfeld, Lukas F. Quiring, Eva Al-Saeedi, Mohammed Nusshag, Christian Büchler, Markus W. Schneider, Martin |
author_facet | Liesenfeld, Lukas F. Quiring, Eva Al-Saeedi, Mohammed Nusshag, Christian Büchler, Markus W. Schneider, Martin |
author_sort | Liesenfeld, Lukas F. |
collection | PubMed |
description | BACKGROUND: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity, in particular by inducing acute kidney injury (AKI). Factors contributing to occurrence of AKI after intraperitoneal perfusion with CDDP have not been sufficiently evaluated. PATIENTS AND METHODS: Data from 63 patients treated with a CDDP-containing HIPEC regimen were retrospectively analyzed concerning demographics, underlying disease, surgery, and HIPEC details to evaluate risk factors of AKI. A preclinical rat perfusion model was applied to assess the influence of temperature, concentration, perfusate volume, perfusion flow rate, and extent of peritonectomy on drug absorption upon intraperitoneal CDDP perfusion. RESULTS: AKI occurred in 66.1% of patients undergoing CDDP-containing HIPEC, with total intraoperative fluid influx being a negative and the extent of parietal peritonectomy being a positive independent predictor of postoperative AKI. In a preclinical model, bilateral anterior parietal peritonectomy significantly increased systemic CDDP absorption by 1.6 to 2-fold. CDDP plasma levels in animals were significantly higher after both perfusion with increased CDDP perfusate concentrations and bilateral anterior parietal peritonectomy. CONCLUSION: CDDP-containing HIPEC is associated with relevant morbidity owing to its systemic toxicity. Extent of parietal peritonectomy is an independent predictor of AKI. CDDP dose reduction should be considered in case of extensive parietal peritonectomy. Cytostatic drug concentrations in HIPEC perfusate should be paid more attention to than total dose per body surface area. Further clinical studies are needed to confirm the presented preclinical findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-12661-3. |
format | Online Article Text |
id | pubmed-10085927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-100859272023-04-12 Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury Liesenfeld, Lukas F. Quiring, Eva Al-Saeedi, Mohammed Nusshag, Christian Büchler, Markus W. Schneider, Martin Ann Surg Oncol Peritoneal Surface Malignancy BACKGROUND: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity, in particular by inducing acute kidney injury (AKI). Factors contributing to occurrence of AKI after intraperitoneal perfusion with CDDP have not been sufficiently evaluated. PATIENTS AND METHODS: Data from 63 patients treated with a CDDP-containing HIPEC regimen were retrospectively analyzed concerning demographics, underlying disease, surgery, and HIPEC details to evaluate risk factors of AKI. A preclinical rat perfusion model was applied to assess the influence of temperature, concentration, perfusate volume, perfusion flow rate, and extent of peritonectomy on drug absorption upon intraperitoneal CDDP perfusion. RESULTS: AKI occurred in 66.1% of patients undergoing CDDP-containing HIPEC, with total intraoperative fluid influx being a negative and the extent of parietal peritonectomy being a positive independent predictor of postoperative AKI. In a preclinical model, bilateral anterior parietal peritonectomy significantly increased systemic CDDP absorption by 1.6 to 2-fold. CDDP plasma levels in animals were significantly higher after both perfusion with increased CDDP perfusate concentrations and bilateral anterior parietal peritonectomy. CONCLUSION: CDDP-containing HIPEC is associated with relevant morbidity owing to its systemic toxicity. Extent of parietal peritonectomy is an independent predictor of AKI. CDDP dose reduction should be considered in case of extensive parietal peritonectomy. Cytostatic drug concentrations in HIPEC perfusate should be paid more attention to than total dose per body surface area. Further clinical studies are needed to confirm the presented preclinical findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-12661-3. Springer International Publishing 2022-12-10 2023 /pmc/articles/PMC10085927/ /pubmed/36496489 http://dx.doi.org/10.1245/s10434-022-12661-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Peritoneal Surface Malignancy Liesenfeld, Lukas F. Quiring, Eva Al-Saeedi, Mohammed Nusshag, Christian Büchler, Markus W. Schneider, Martin Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury |
title | Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury |
title_full | Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury |
title_fullStr | Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury |
title_full_unstemmed | Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury |
title_short | Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury |
title_sort | extensive peritonectomy is an independent risk factor for cisplatin hipec-induced acute kidney injury |
topic | Peritoneal Surface Malignancy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085927/ https://www.ncbi.nlm.nih.gov/pubmed/36496489 http://dx.doi.org/10.1245/s10434-022-12661-3 |
work_keys_str_mv | AT liesenfeldlukasf extensiveperitonectomyisanindependentriskfactorforcisplatinhipecinducedacutekidneyinjury AT quiringeva extensiveperitonectomyisanindependentriskfactorforcisplatinhipecinducedacutekidneyinjury AT alsaeedimohammed extensiveperitonectomyisanindependentriskfactorforcisplatinhipecinducedacutekidneyinjury AT nusshagchristian extensiveperitonectomyisanindependentriskfactorforcisplatinhipecinducedacutekidneyinjury AT buchlermarkusw extensiveperitonectomyisanindependentriskfactorforcisplatinhipecinducedacutekidneyinjury AT schneidermartin extensiveperitonectomyisanindependentriskfactorforcisplatinhipecinducedacutekidneyinjury |